Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium

Autor: Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group

Publikováno v: Neesgaard, B, Mocroft, A, Zangerle, R, Wit, F, Lampe, F, Günthard, H F, Necsoi, C, Law, M, Mussini, C, Castagna, A, Monforte, A DA, Pradier, C, Chkhartisvilli, N, Reyes-Uruena, J, Vehreschild, J J, Wasmuth, J-C, Sönnerborg, A, Stephan, C, Greenberg, L, Llibre, J M, Volny-Anne, A, Peters, L, Pelchen-Matthews, A, Vannappagari, V, Gallant, J, Rieger, A, Youle, M, Braun, D, De Wit, S, Petoumenos, K, Borghi, V, Spagnuolo, V, Tsertsvadze, T, Lundgren, J, Ryom, L & RESPOND Study Group 2020, ' Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting : The RESPOND cohort consortium ', PLoS ONE, vol. 15, no. 12, e0243625 . https://doi.org/10.1371/journal.pone.0243625
PLoS ONE
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
PLoS ONE, Vol 15, Iss 12, p e0243625 (2020)
PLoS ONE, 15(12 December):e0243625. Public Library of Science
PloS one, 15 (12 December

Objectives To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-lif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b7e1131f1db9907055718899d452b1

Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor–Based Antiretroviral Therapy

Autor: Pornchai Techakunakorn, Marc Lallemant, Kenneth McIntosh, Rapeepan Suaysod, Sawitree Krikajornkitti, Suwalai Chalermpantmetagul, Nicolas Salvadori, Sakulrat Srirojana, Nicole Ngo-Giang-Huong, Tim R. Cressey, Laddawan Laomanit, Sophie Le Cœur, Suparat Kanjanavanit, Gonzague Jourdain, Patrinee Traisathit

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2015, 61 (1), pp.95-101. ⟨10.1093/cid/civ271⟩

Background. Human immunodeficiency virus (HIV)-infected children failing second-line antiretroviral therapy (ART) have no access to third-line antiretroviral drugs in many resource-limited settings. It is important to identify risk factors for second

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef5c977dbd544464c8406b1d90f1725
https://doi.org/10.1093/cid/civ271

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study

Autor: Milos Opravil, Huldrych F. Günthard, Hansjakob Furrer, Sabine Yerly, Viktor von Wyl, Heiner C. Bucher, Enos Bernasconi, Marcel Wolbers, Bernard Hirschel, Pietro Vernazza, Manuel Battegay, Matthias Cavassini

Publikováno v: AIDS, Vol. 21, No 16 (2007) pp. 2201-2207

OBJECTIVE: To investigate predictors of continued HIV RNA viral load suppression in individuals switched to abacavir (ABC), lamivudine (3TC) and zidovudine (ZDV) after successful previous treatment with a protease inhibitor or non-nucleoside reverse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec79c128fb782af714ed7f6d83341028
https://ora.ox.ac.uk/objects/uuid:828c5356-d01f-4a38-8056-544955900430

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Autor: M M L Wong, Kwok-Yung Yuen, Ivan Hung, K S Chan, Richard Y.T. Kao, V C C Cheng, K H Chan, Yi Guan, Joseph S. M. Peiris, C L P Wong, Chung-Ming Chu, Leo L.M. Poon

Publikováno v: Thorax

Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b51de7430ebed23b3b6bedc9666d2541

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients

Autor: Alexandra U Scherrer, Bruno Ledergerber, Viktor von Wyl, Jürg Böni, Sabine Yerly, Thomas Klimkait, Cristina Cellerai, Hansjakob Furrer, Alexandra Calmy, Matthias Cavassini, Luigia Elzi, Pietro L Vernazza, Enos Bernasconi, Huldrych F Günthard, Swiss HIV Cohort Study

Publikováno v: PLOS ONE, Vol. 7, No 6 (2012) P. e37983
PLoS ONE, Vol 7, Iss 6, p e37983 (2012)
PLoS ONE; Vol 7
PloS one
PLoS ONE
Scherrer, Alexandra U.; Ledergerber, Bruno; von Wyl, Viktor; Böni, Jürg; Yerly, Sabine; Klimkait, Thomas; Cellerai, Cristina; Furrer, Hansjakob; Calmy, Alexandra; Cavassini, Matthias; Elzi, Luigia; Vernazza, Pietro L.; Bernasconi, Enos; Günthard, Huldrych F.; Swiss HIV Cohort Study, (2012). Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. PLoS ONE, 7(6), e37983. Lawrence, Kans.: Public Library of Science 10.1371/journal.pone.0037983
Plos One, vol. 7, no. 6, pp. e37983

Background Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naive patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7322ddc0fddb37cfc7322f0a1a05e5f5
https://doi.org/10.5167/uzh-67852